Novavax Inc (NVAX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.41B
Last updated: Nov 17, 2026 at 11:06 AM ET
Novavax Inc (NVAX) Earnings: Report Dates and Results
Novavax (NVAX) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Novavax reported EPS of -$0.19, above the -$0.37 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
NVAX has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 400.0% above the $0.11 reported for the quarter ended Dec 31, 2025.
NVAX Earnings Call
The latest NVAX earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, NVAX beat 20, missed 19 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $68.30M, down 3.0% from $70.44M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.19 | -$0.37 | -$0.49 - -$0.23 | +48.65% | Beat | N/A | 7 | 1 up, 2 down | Nov 5, 2026 | $68.30M |
| Jun 30, 2026 | -$0.32 | -$0.36 | -$0.50 - -$0.25 | +11.11% | Beat | -151.6% | 8 | 0 up, 4 down | Aug 6, 2026 | $56.70M |
| Mar 31, 2026 | -$0.06 | -$0.37 | -$0.39 - -$0.06 | +83.78% | Beat | -102.0% | 7 | 1 up, 0 down | May 6, 2026 | $139.51M |
| Dec 31, 2025 | $0.11 | -$0.66 | -$1.36 - -$0.11 | +116.67% | Beat | N/A | 7 | 0 up, 0 down | Feb 26, 2026 | $147.14M |
| Sep 30, 2025 | -$0.47 | -$1.13 | -$1.51 - -$0.19 | +58.41% | Beat | N/A | 7 | 0 up, 2 down | Nov 6, 2025 | $70.44M |
| Jun 30, 2025 | $0.62 | $0.06 | -$0.64 - $0.39 | +933.33% | Beat | -37.4% | 5 | 1 up, 1 down | Aug 6, 2025 | $239.24M |
| Mar 31, 2025 | $2.93 | $0.71 | -$0.58 - $2.67 | +312.68% | Beat | N/A | 5 | 1 up, 0 down | May 8, 2025 | $666.65M |
| Dec 31, 2024 | -$0.52 | -$0.51 | -$1.12 - $0.46 | -1.21% | Miss | N/A | 5 | 0 up, 3 down | Feb 27, 2025 | $88.31M |
| Sep 30, 2024 | -$0.76 | -$0.75 | -$1.09 - -$0.46 | -1.33% | Miss | N/A | 4 | 0 up, 0 down | Nov 12, 2024 | $84.51M |
| Jun 30, 2024 | $0.99 | $1.70 | $0.41 - $2.56 | -41.76% | Miss | +70.7% | 4 | 1 up, 1 down | Aug 8, 2024 | $415.48M |
| Mar 31, 2024 | -$1.05 | -$1.06 | -$1.48 - -$0.85 | +0.94% | Beat | N/A | 5 | 0 up, 0 down | May 10, 2024 | $93.86M |
| Dec 31, 2023 | -$1.44 | -$0.35 | -$1.29 - $0.08 | -311.43% | Miss | N/A | 6 | 1 up, 0 down | Feb 28, 2024 | $291.34M |
| Sep 30, 2023 | -$1.26 | -$2.21 | -$2.79 - $0.28 | +42.99% | Beat | N/A | 6 | 0 up, 1 down | Nov 9, 2023 | $186.99M |
| Jun 30, 2023 | $0.58 | -$1.16 | -$2.50 - -$0.40 | +150.00% | Beat | N/A | 6 | 1 up, 0 down | Aug 8, 2023 | $424.43M |
| Mar 31, 2023 | -$3.41 | -$3.46 | -$3.86 - -$3.05 | +1.45% | Beat | -233.2% | 5 | 0 up, 1 down | May 9, 2023 | $80.95M |
| Dec 31, 2022 | -$2.28 | -$1.05 | -$1.44 - -$0.42 | -117.14% | Miss | N/A | 4 | 1 up, 0 down | Feb 28, 2023 | $357.40M |
| Sep 30, 2022 | -$2.15 | $1.59 | -$0.81 - $3.76 | -235.22% | Miss | N/A | 6 | 1 up, 1 down | Nov 8, 2022 | $734.58M |
| Jun 30, 2022 | -$6.53 | $5.18 | $4.62 - $7.09 | -226.06% | Miss | N/A | 6 | 0 up, 1 down | Aug 8, 2022 | $185.93M |
| Mar 31, 2022 | $2.56 | $2.65 | $1.30 - $3.86 | -3.40% | Miss | N/A | 6 | 0 up, 0 down | May 9, 2022 | $703.97M |
| Dec 31, 2021 | -$11.18 | -$1.80 | -$5.16 - $7.89 | -521.11% | Miss | N/A | 5 | 0 up, 2 down | Feb 28, 2022 | $222.20M |
| Sep 30, 2021 | -$4.31 | -$3.55 | -$5.04 - -$2.47 | -21.41% | Miss | N/A | 6 | 1 up, 0 down | Nov 4, 2021 | $178.84M |
| Jun 30, 2021 | -$4.75 | -$3.25 | -$6.51 - -$1.29 | -46.15% | Miss | N/A | 5 | N/A | Aug 5, 2021 | $298.02M |
| Mar 31, 2021 | -$3.05 | -$3.60 | -$7.39 - -$1.02 | +15.28% | Beat | N/A | 5 | N/A | May 10, 2021 | $447.23M |
| Dec 31, 2020 | -$2.70 | -$1.49 | -$2.16 - -$0.68 | -81.21% | Miss | N/A | 6 | N/A | Mar 1, 2021 | $318.57M |
| Sep 30, 2020 | -$3.21 | $1.73 | -$1.02 - $8.22 | -285.55% | Miss | N/A | 5 | N/A | Nov 9, 2020 | $157.02M |
| Jun 30, 2020 | -$0.30 | -$0.33 | -$0.94 - $0.48 | +9.09% | Beat | N/A | 5 | N/A | Aug 10, 2020 | N/A |
| Mar 31, 2020 | -$0.58 | -$0.67 | -$1.19 - -$0.61 | +13.43% | Beat | N/A | 7 | N/A | May 11, 2020 | N/A |
| Dec 31, 2019 | -$1.13 | -$1.06 | -$1.39 - -$0.60 | -6.60% | Miss | N/A | 7 | N/A | Mar 11, 2020 | $8.82M |
| Sep 30, 2019 | -$1.11 | -$0.89 | -$1.23 - -$0.69 | -24.72% | Miss | N/A | 6 | N/A | Nov 7, 2019 | $2.51M |
| Jun 30, 2019 | -$1.69 | -$1.59 | -$1.86 - -$1.38 | -6.29% | Miss | N/A | 7 | N/A | Aug 7, 2019 | $3.36M |
| Mar 31, 2019 | -$2.20 | -$2.26 | -$2.60 - -$1.60 | +2.65% | Beat | N/A | 8 | N/A | May 2, 2019 | $3.98M |
| Dec 31, 2018 | -$2.60 | -$2.60 | -$2.60 - -$1.80 | 0.00% | In line | N/A | 9 | N/A | Mar 18, 2019 | N/A |
| Sep 30, 2018 | -$2.40 | -$2.52 | -$3.00 - -$1.80 | +4.76% | Beat | N/A | 6 | N/A | Nov 7, 2018 | $7.74M |
| Jun 30, 2018 | -$2.40 | -$2.46 | -$2.80 - -$2.20 | +2.44% | Beat | N/A | 8 | N/A | Aug 8, 2018 | $10.77M |
| Mar 31, 2018 | -$2.80 | -$2.78 | -$3.00 - -$2.20 | -0.72% | Miss | N/A | 7 | N/A | May 9, 2018 | $9.65M |
| Dec 31, 2017 | -$3.20 | -$3.09 | -$3.60 - -$2.80 | -3.56% | Miss | N/A | 8 | N/A | Mar 14, 2018 | $10.41M |
| Sep 30, 2017 | -$3.00 | -$3.19 | -$3.40 - -$3.00 | +5.96% | Beat | N/A | 7 | N/A | Nov 7, 2017 | $8.35M |
| Jun 30, 2017 | -$3.20 | -$3.17 | -$3.40 - -$3.00 | -0.95% | Miss | N/A | 7 | N/A | Aug 8, 2017 | $6.73M |
| Mar 31, 2017 | -$3.20 | -$3.47 | N/A | +7.78% | Beat | N/A | N/A | N/A | May 8, 2017 | $5.68M |
| Dec 31, 2016 | -$4.20 | -$4.58 | N/A | +8.30% | Beat | N/A | N/A | N/A | Feb 27, 2017 | $5.40M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $3.19, a profit after a loss of $1.34 per share the year before. It was -$20.60 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $3.19 | N/A |
| Dec 31, 2024 | -$1.34 | N/A |
| Dec 31, 2023 | -$5.53 | N/A |
| Dec 31, 2022 | -$8.40 | N/A |
| Dec 31, 2021 | -$23.29 | N/A |
| Dec 31, 2020 | -$6.79 | N/A |
| Dec 31, 2019 | -$6.13 | N/A |
| Dec 31, 2018 | -$10.20 | N/A |
| Dec 31, 2017 | -$12.60 | N/A |
| Dec 31, 2016 | -$20.60 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,200 words across 14 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 9,154 | 14 | |
| 2026Q2 | Jun 30, 2026 | 7,828 | 14 | |
| 2026Q1 | Mar 31, 2026 | 9,884 | 12 | |
| 2025Q4 | Dec 31, 2025 | 2,384 | 9 | |
| 2025Q3 | Sep 30, 2025 | 8,360 | 13 | |
| 2025Q2 | Jun 30, 2025 | 7,805 | 12 | |
| 2025Q1 | Mar 31, 2025 | 7,110 | 12 | |
| 2024Q4 | Dec 31, 2024 | 8,230 | 13 |
2026Q3 Earnings Call
Opening remarks
Naina Zaman Investor Relations Good morning, and thank you for joining us today to discuss our third quarter financial results and operational highlights on November 5, 2026. A press release announcing our results is available on our website at www.novavax.com, and an audio archive of this conference call will be available on our website later today. Before we begin with our prepared remarks, I would like to remind you that this presentation includes forward-looking statements regarding Novavax's current expectations related to, but not limited to, its partnerships, market opportunities, and financial guidance. Our actual results may be materially different from such statements, as detailed in the presentation. Discussions of non-GAAP figures and reconciliations to GAAP figures are available in our earnings press release and presentation. Descriptions of the risks and uncertainties associated with Novavax are included in our SEC filings. These can be accessed through our website. Joining me today are John Jacobs, our President and CEO; Elaine O'Hara, Chief Strategy Officer; Dr. Bob Walker, Head of R&D; and Jim Kelly, our Chief Financial Officer. I would now like to hand the call over to John.
John Jacobs President and CEO Thank you, Naina, and welcome, everyone. As we near the end of 2026, I'm pleased with the progress we have made this year across the three pillars of our strategy: partnering our vaccine technology, driving targeted and capital-efficient R&D innovation, and maintaining a lean and agile operating model. For those new to our story, Novavax is a vaccine technology company focused on creating long-term value through partnerships. We believe our technology can underpin a broad range of vaccines in infectious disease, from viral to bacterial, and we are in the early stages of exploring its potential in oncology. By combining our own innovation with that of our partners and leveraging their manufacturing scale and commercial reach, we aim to expand access to our technology, unlock new opportunities, and build a legacy of lasting impact on global health. Our technology platform is the engine behind our business, built on a proven foundation in infectious disease. Today, it is used in two commercial vaccines, Nuvaxovid for COVID-19 and R21/Matrix-M for malaria. Both have demonstrated protection against serious disease and favorable tolerability at population scale, with R21/Matrix-M extending that impact to children as young as five months old in malaria-endemic regions. Our technology is also being applied in some of the most attractive vaccine markets. Sanofi recently initiated its phase III influenza COVID-19 combination vaccine trial in Europe. Sanofi management confirmed to us that they are targeting a U.S. phase III start in 2027 to support U.S. approval. The trial in Europe utilizes Novavax's differentiated COVID-19 vaccine and Sanofi's market-leading Fluzone High-Dose influenza vaccine.
Frequently Asked Questions About NVAX
When is Novavax's next earnings date?
Novavax's next earnings report is expected for Feb 24, 2027.
Did NVAX beat earnings estimates last quarter?
Yes. Novavax reported EPS of -$0.19 for the quarter ended Sep 30, 2026, above the -$0.37 estimate, a 48.65% surprise.
What EPS do analysts expect from NVAX next quarter?
The consensus EPS estimate for Novavax for the quarter ending Dec 31, 2026 is $0.55 from 10 analysts, with estimates from $0.18 to $0.98.
How often does NVAX beat earnings estimates?
Novavax beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +195.43%.
NVAX pages: Overview, Earnings, Forecast, Financials, Competitors